Quantity of qualified people: CDEC reviewed the uncertainty in the volume of patients with moderately critical to serious hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical industry experts consulted by CADTH indicated that some sufferers who're categorized as owning moderate or average condition can have a significant bleeding phenotype, https://caidenrxzaa.blogsuperapp.com/36600808/examine-this-report-on-hemgenix